GlassScriptPhysician profile
Heather D Vick
NPI 1396305694
$9,110.71
in general payments reported to CMS, 2019-2025
37 companies · $55.51 in 2025
The $55.51 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,605 · 2022: $1,913 · 2023: $4,089 · 2024: $448 · 2025: $55.51.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,464 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,463.78 |
| Education | $129.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,305.09 | 2021-2023 | Tecvayli, Darzalex, Carvykti |
| Celgene Corporation | $978.11 | 2021-2023 | Reblozyl, Pomalyst, Onureg |
| Astrazeneca Pharmaceuticals LP | $974.31 | 2021-2024 | Enhertu, Lynparza, Calquence |
| Daiichi Sankyo INC. | $476.20 | 2021-2025 | Injectafer, Datroway, Vanflyta |
| Sanofi-Aventis U.S. LLC | $473.63 | 2021-2024 | |
| Genentech USA, INC. | $437.67 | 2022-2023 | Lunsumio |
| Astellas Pharma US INC | $377.69 | 2022-2024 | Vyloy, Cresemba, Xtandi |
| Seagen INC. | $366.57 | 2021-2023 | Adcetris |
| Amgen INC. | $301.03 | 2021-2023 | Xgeva, Nplate, Kyprolis |
| Abbvie INC. | $280.81 | 2023 | |
| Eisai INC. | $255.99 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $255.21 | 2021-2023 | Imbruvica, Epkinly |
| Coherus Oncology, INC. | $253.55 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $241.36 | 2023 | Reblozyl |
| Gilead Sciences, INC. | $233.75 | 2023-2024 | Trodelvy |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $208.13 | 2023-2024 | |
| Lilly USA, LLC | $195.86 | 2021-2023 | Jaypirca |
| Incyte Corporation | $195.56 | 2021-2023 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $156.47 | 2023 | Iclusig |
| Pharmaessentia USA Corporation | $148.50 | 2023 | Besremi |
| Kyowa Kirin, INC. | $122.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $112.08 | 2022-2023 | |
| Beigene USA, INC. | $108.39 | 2021-2023 | Brukinsa |
| Sobi, INC | $107.38 | 2022 | |
| Kite Pharma, INC. | $96.19 | 2022 | |
| Genzyme Corporation | $94.22 | 2023 | |
| Glaxosmithkline, LLC. | $90.80 | 2021 | |
| Karyopharm Therapeutics INC. | $40.42 | 2023 | Xpovio |
| Merck Sharp & Dohme LLC | $39.94 | 2021-2022 | |
| Adaptive Biotechnologies Corporation | $29.86 | 2023 | Clonoseq |
| Cti Biopharma Corp. | $28.48 | 2023 | Vonjo |
| Sumitomo Pharma America, INC. | $26.74 | 2025 | Orgovyx |
| Rigel Pharmaceuticals, INC. | $25.61 | 2023 | Rezlidhia, Tavalisse |
| Foundation Medicine, INC. | $21.84 | 2022 | |
| Adc Therapeutics America, INC. | $18.58 | 2023 | |
| Morphosys, US INC. | $17.21 | 2023 | Monjuvi |
| Acrotech Biopharma INC. | $15.41 | 2024 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Vick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.